Key terms
About MCRB
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MCRB news
Mar 06
8:14am ET
Seres Therapeutics price target lowered to $5 from $9 at Oppenheimer
Mar 06
7:55am ET
Oppenheimer Sticks to Its Buy Rating for Seres Therapeutics (MCRB)
Mar 06
7:33am ET
Seres Therapeutics price target lowered to $8 from $10 at Chardan
Mar 06
1:01am ET
A New Cause for Concern: Seres Therapeutics Inc. Adds a New Supply Chain Risk
Mar 05
11:55pm ET
Seres Therapeutics (MCRB) Gets a Buy from TD Cowen
Feb 26
7:22am ET
Seres Therapeutics Announces Executive Leadership Transition and New CFO Compensation Details
Feb 26
7:08am ET
Seres Therapeutics appoints Marella Thorell CFO amid Arkowitz retirement
Feb 06
7:35pm ET
Sell Rating on Seres Therapeutics Amid Underperforming Sales and Financial Challenges
Jan 12
11:36am ET
Biotech Alert: Searches spiking for these stocks today
Jan 11
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 11
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 09
12:00pm ET
Analysts Offer Insights on Healthcare Companies: Cellectar Biosciences (CLRB) and Seres Therapeutics (MCRB)
Dec 07
7:49pm ET
Seres Therapeutics announces presentation of PK/PD and safety data in SER-155
No recent press releases are available for MCRB
MCRB Financials
Key terms
Ad Feedback
MCRB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MCRB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range